ACE and chronic kidney disease: While contemporary trials in people with CKD have required the use of maximally tolerated angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) as background therapy, detailed data on the initiation and combination of therapies are lacking for individuals with CKD and T2D, especially on whether these drugs should be sequentially or simultaneously initiated.